Company profile
Currus Biologics Pty Ltd
Unlocking CAR T-cell therapy for solid tumours with the BEAT platform
- Industry
- Biotechnology Research
- Employees
- 12
- Headquarters
- Melbourne, Victoria
- Founded
- 2021
- LinkedIn followers
- 1,122
- Office locations
- 1
Currus Biologics Pty Ltd company summary
Currus Biologics Pty Ltd is a company in the Biotechnology Research industry, headquartered in Melbourne, Victoria, founded in 2021. On LinkedIn the company has around 12 employees and 1,122 followers.
What technology does Currus Biologics Pty Ltd use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Currus Biologics Pty Ltd
Currus Biologics is developing its proprietary BEAT (Bispecific Engagers of Antigen Presenting Cells and T cells) platform to unlock CAR T-cell therapy for solid tumours. The BEAT (Bispecific Engagers of Antigen presenting cells and T cells) is a universal solution compatible with any CAR T-cell format or tumour target, able to rewire immune activation by simultaneously engaging antigen-presenting cells (APCs) and CAR T-cells to overcome the biological barriers that have limited CAR T-cell efficacy in solid tumours. The Company’s approach prevents CAR T-cell exhaustion, drives durable proliferation and persistence, remodels the tumour microenvironment, and promotes epitope spreading, enabling robust and sustained anti-tumour responses. Supported by robust preclinical data and independent academic validation, the BEAT technology provides a cost-effective, flexible add-on, enabling partners to unlock their technology and deliver life-changing outcomes for patients. Currus Biologics is a privately held biotechnology company based in Melbourne, Australia, backed by Brandon Capital Partners, Main Sequence Ventures, and Uniseed.
Where is Currus Biologics Pty Ltd located?
Currus Biologics Pty Ltd lists 1 location.
Compare companies similar to Currus Biologics Pty Ltd
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Currus Biologics Pty Ltd currusbio.com | Biotechnology Research | 12 | 2021 | Melbourne, Victoria |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Currus Biologics Pty Ltd
What does Currus Biologics Pty Ltd do?
Currus Biologics is developing its proprietary BEAT (Bispecific Engagers of Antigen Presenting Cells and T cells) platform to unlock CAR T-cell therapy for solid tumours. The BEAT (Bispecific Engagers of Antigen presenting cells and T cells) is a universal solution compatible with any CAR T-cell format or tumour target, able to rewire immune activation by simultaneously engaging antigen-presenting cells (APCs) and CAR T-cells to overcome the biological barriers that have limited CAR T-cell efficacy in solid tumours. The Company’s approach prevents CAR T-cell exhaustion, drives durable proliferation and persistence, remodels the tumour microenvironment, and promotes epitope spreading, enabling robust and sustained anti-tumour responses. Supported by robust preclinical data and independent academic validation, the BEAT technology provides a cost-effective, flexible add-on, enabling partners to unlock their technology and deliver life-changing outcomes for patients. Currus Biologics is a privately held biotechnology company based in Melbourne, Australia, backed by Brandon Capital Partners, Main Sequence Ventures, and Uniseed.
How many employees does Currus Biologics Pty Ltd have?
Currus Biologics Pty Ltd has around 12 employees on LinkedIn.
Where is Currus Biologics Pty Ltd headquartered?
Currus Biologics Pty Ltd is headquartered in Melbourne, Victoria.
When was Currus Biologics Pty Ltd founded?
Currus Biologics Pty Ltd was founded in 2021.
Build a lead list from companies like Currus Biologics Pty Ltd
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.